Search

Your search keyword '"Arriaga-Canon, Cristian"' showing total 34 results
Start Over Author "Arriaga-Canon, Cristian" Search Limiters Full Text
34 results on '"Arriaga-Canon, Cristian"'

1. Transcriptome Analysis Identifies GATA3-AS1 as a Long Noncoding RNA Associated with Resistance to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

Author

Contreras-Espinosa, Laura, Alcaraz, Nicolás, De La Rosa-Velázquez, Inti A., Díaz-Chávez, José, Cabrera-Galeana, Paula, Rebollar-Vega, Rosa, Reynoso-Noverón, Nancy, Maldonado-Martínez, Héctor A., González-Barrios, Rodrigo, Montiel-Manríquez, Rogelio, Bautista-Sánchez, Diana, Castro-Hernández, Clementina, Alvarez-Gomez, Rosa M., Jiménez-Trejo, Francisco, Tapia-Rodríguez, Miguel, García-Gordillo, José A., Pérez-Rosas, Augusto, Bargallo-Rocha, Enrique, Arriaga-Canon, Cristian, and Herrera, Luis A.

Published
2021
Full Text
View/download PDF

2. Saliva is a reliable and accessible source for the detection of SARS-CoV-2

Author

Herrera, Luis A., Hidalgo-Miranda, Alfredo, Reynoso-Noverón, Nancy, Meneses-García, Abelardo A., Mendoza-Vargas, Alfredo, Reyes-Grajeda, Juan P., Vadillo-Ortega, Felipe, Cedro-Tanda, Alberto, Peñaloza, Fernando, Frías-Jimenez, Emmanuel, Arriaga-Canon, Cristian, Ruiz, Rosaura, Angulo, Ofelia, López-Villaseñor, Imelda, Amador-Bedolla, Carlos, Vilar-Compte, Diana, Cornejo, Patricia, Cisneros-Villanueva, Mireya, Hurtado-Cordova, Eduardo, Cendejas-Orozco, Mariana, Hernández-Morales, José S., Moreno, Bernardo, Hernández-Cruz, Irwin A., Herrera, César A., García, Francisco, González-Woge, Miguel A., Munguía-Garza, Paulina, Luna-Maldonado, Fernando, Sánchez-Vizcarra, Antonia, Osnaya, Vincent G., Medina-Molotla, Nelly, Alfaro-Mora, Yair, Cáceres-Gutiérrez, Rodrigo E., Tolentino-García, Laura, Rosas-Escobar, Patricia, Román-González, Sergio A., Escobar-Arrazola, Marco A., Canseco-Méndez, Julio C., Ortiz-Soriano, Diana R., Domínguez-Ortiz, Julieta, González-Barrera, Ana D., Aparicio-Bautista, Diana I., Cruz-Rangel, Armando, Alarcón-Zendejas, Ana Paula, Contreras-Espinosa, Laura, González, Rodrigo, Guerra-Calderas, Lissania, Meraz-Rodríguez, Marco A., Montalvo-Casimiro, Michel, Montiel-Manríquez, Rogelio, Torres-Arciga, Karla, Venegas, Daniela, Juárez-González, Vasti, Guajardo-Barreto, Xiadani, Monroy-Martínez, Verónica, Guillén, Daniel, Fernández, Jacquelina, Herrera, Juliana, León-Rodriguez, Renato, Canela-Pérez, Israel, Ruíz-Ordaz, Blanca H., Valdez-Vazquez, Rafael, Bertin-Montoya, Jennifer, Niembro-Ortega, María, Villegas-Acosta, Liudmila, López-Castillo, Daniela, Soriano-Ríos, Andrea, Gastelum-Ramos, Michael, Zamora-Barandas, Tonatiuh, Morales-Baez, Jorge, García-Rodríguez, María, García-Martínez, Mariano, Nieto-Patlán, Erik, Quirasco-Baruch, Maricarmen, López-Martínez, Irma, Ramírez-Gonzalez, Ernesto, Olivera-Díaz, Hiram, and Escobar-Escamilla, Noe

Published
2021
Full Text
View/download PDF

4. The Expression Profiles of lncRNAs Are Associated with Neoadjuvant Chemotherapy Resistance in Locally Advanced, Luminal B-Type Breast Cancer.

Author

González-Woge, Miguel, Contreras-Espinosa, Laura, García-Gordillo, José Antonio, Aguilar-Villanueva, Sergio, Bargallo-Rocha, Enrique, Cabrera-Galeana, Paula, Vasquez-Mata, Tania, Cervantes-López, Ximena, Vargas-Lías, Diana Sofía, Montiel-Manríquez, Rogelio, Bautista-Hinojosa, Luis, Rebollar-Vega, Rosa, Castro-Hernández, Clementina, Álvarez-Gómez, Rosa María, De La Rosa-Velázquez, Inti Alberto, Díaz-Chávez, José, Jiménez-Trejo, Francisco, Arriaga-Canon, Cristian, and Herrera, Luis Alonso

Subjects
NUCLEIC acid hybridization, GENE expression, BREAST cancer, NEOADJUVANT chemotherapy, PHENOTYPES
Abstract

lncRNAs are noncoding transcripts with tissue and cancer specificity. Particularly, in breast cancer, lncRNAs exhibit subtype-specific expression; they are particularly upregulated in luminal tumors. However, no gene signature-based laboratory tests have been developed for luminal breast cancer identification or the differential diagnosis of luminal tumors, since no luminal A- or B-specific genes have been identified. Particularly, luminal B patients are of clinical interest, since they have the most variable response to neoadjuvant treatment; thus, it is necessary to develop diagnostic and predictive biomarkers for these patients to optimize treatment decision-making and improve treatment quality. In this study, we analyzed the lncRNA expression profiles of breast cancer cell lines and patient tumor samples from RNA-Seq data to identify an lncRNA signature specific for luminal phenotypes. We identified an lncRNA signature consisting of LINC01016, GATA3-AS1, MAPT-IT1, and DSCAM-AS1 that exhibits luminal subtype-specific expression; among these lncRNAs, GATA3-AS1 is associated with the presence of residual disease (Wilcoxon test, p < 0.05), which is related to neoadjuvant chemotherapy resistance in luminal B breast cancer patients. Furthermore, analysis of GATA3-AS1 expression using RNA in situ hybridization (RNA ISH) demonstrated that this lncRNA is detectable in histological slides. Similar to estrogen receptors and Ki67, both commonly detected biomarkers, GATA3-AS1 proves to be a suitable predictive biomarker for clinical application in breast cancer laboratory tests. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Association of SLC12A1 and GLUR4 Ion Transporters with Neoadjuvant Chemoresistance in Luminal Locally Advanced Breast Cancer

Author

Justo-Garrido, Montserrat, primary, López-Saavedra, Alejandro, additional, Alcaraz, Nicolás, additional, Cortés-González, Carlo C., additional, Oñate-Ocaña, Luis F., additional, Caro-Sánchez, Claudia Haydee Sarai, additional, Castro-Hernández, Clementina, additional, Arriaga-Canon, Cristian, additional, Díaz-Chávez, José, additional, and Herrera, Luis A., additional

Published
2023
Full Text
View/download PDF

8. Downregulation of Serotonergic System Components in an Experimentally Induced Cryptorchidism in Rabbits.

Author

Jiménez-Trejo, Francisco, Arriaga-Canon, Cristian, Herrera, Luis A., Coronado-Mares, Isabel, Montiel-Manríquez, Rogelio, González-Santoyo, Isaac, Pérez-Báez, Wendy B., and Tapia-Rodríguez, Miguel

Subjects
*MALE reproductive organs, *RAPHE nuclei, *CRYPTORCHISM, *RABBITS, *EUROPEAN rabbit, *SPERMATOGENESIS, *CARCINOID, *REPRODUCTION, *MALE infertility
Abstract

Cryptorchidism (CO) or undescended testes is defined as the failure of one or both testes to be positioned inside the scrotum. Typically, cryptorchidism is detected at birth or shortly thereafter, and in humans, it is considered to be part of the testicular dysgenesis syndrome (TDS), a complex pathology regarding the male reproductive system that apparently involves the interaction of both genetic and environmental harmful factors, mainly during embryonic development. Serotonin (5-HT) is an ancient molecule that participates in a broad range of body functions, and in recent years, its importance in reproduction has started to be elucidated. In male pathologies such as infertility, varicocele, erectile dysfunction, and primary carcinoid tumors, an increase in 5-HT concentration or its metabolites in the blood, semen, and urine has been directly related; nevertheless, the role of 5-HT in CO remains unknown. In the present work, our goal was to answer two important questions: (1) whether some serotonergic system components are present in adult male Oryctolagus cuniculus (chinchilla rabbit) and (2) if there are changes in their expression in an experimental model of CO. Using histological, molecular, and biochemical approaches, we found the presence of some serotonergic system components in the adult chinchilla rabbit, and we demonstrated that its expression is downregulated after CO was pharmacologically induced. Although we did not test the role of 5-HT in the etiology of CO, our results suggest that this indoleamine could be important for the regulation of steroidogenesis and spermatogenesis processes in the chinchilla rabbit during adulthood. Finally, in parallel experimental series, we found downregulation of kynurenine concentration in COI rabbits when compared to control ones, suggesting that CO could be affecting the kynurenine pathway and probably testicular immune privilege which in turn could lead to infertility/sterility conditions in this disorder. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Association of SLC12A1 and GLUR4 Ion Transporters with Neoadjuvant Chemoresistance in Luminal Locally Advanced Breast Cancer

Author

Justo-Garrido, Montserrat, López-Saavedra, Alejandro, Alcaraz, Nicolás, Cortés-González, Carlo C., Oñate-Ocaña, Luis F., Caro-Sánchez, Claudia Haydee Sarai, Castro-Hernández, Clementina, Arriaga-Canon, Cristian, Díaz-Chávez, José, Herrera, Luis A., Justo-Garrido, Montserrat, López-Saavedra, Alejandro, Alcaraz, Nicolás, Cortés-González, Carlo C., Oñate-Ocaña, Luis F., Caro-Sánchez, Claudia Haydee Sarai, Castro-Hernández, Clementina, Arriaga-Canon, Cristian, Díaz-Chávez, José, and Herrera, Luis A.

Abstract

Chemoresistance to standard neoadjuvant treatment commonly occurs in locally advanced breast cancer, particularly in the luminal subtype, which is hormone receptor-positive and represents the most common subtype of breast cancer associated with the worst outcomes. Identifying the genes associated with chemoresistance is crucial for understanding the underlying mechanisms and discovering effective treatments. In this study, we aimed to identify genes linked to neoadjuvant chemotherapy resistance in 62 retrospectively included patients with luminal breast cancer. Whole RNA sequencing of 12 patient biopsies revealed 269 differentially expressed genes in chemoresistant patients. We further validated eight highly correlated genes associated with resistance. Among these, solute carrier family 12 member 1 (SLC12A1) and glutamate ionotropic AMPA type subunit 4 (GRIA4), both implicated in ion transport, showed the strongest association with chemoresistance. Notably, SLC12A1 expression was downregulated, while protein levels of glutamate receptor 4 (GLUR4), encoded by GRIA4, were elevated in patients with a worse prognosis. Our results suggest a potential link between SLC12A1 gene expression and GLUR4 protein levels with chemoresistance in luminal breast cancer. In particular, GLUR4 protein could serve as a potential target for drug intervention to overcome chemoresistance., Chemoresistance to standard neoadjuvant treatment commonly occurs in locally advanced breast cancer, particularly in the luminal subtype, which is hormone receptor-positive and represents the most common subtype of breast cancer associated with the worst outcomes. Identifying the genes associated with chemoresistance is crucial for understanding the underlying mechanisms and discovering effective treatments. In this study, we aimed to identify genes linked to neoadjuvant chemotherapy resistance in 62 retrospectively included patients with luminal breast cancer. Whole RNA sequencing of 12 patient biopsies revealed 269 differentially expressed genes in chemoresistant patients. We further validated eight highly correlated genes associated with resistance. Among these, solute carrier family 12 member 1 (SLC12A1) and glutamate ionotropic AMPA type subunit 4 (GRIA4), both implicated in ion transport, showed the strongest association with chemoresistance. Notably, SLC12A1 expression was downregulated, while protein levels of glutamate receptor 4 (GLUR4), encoded by GRIA4, were elevated in patients with a worse prognosis. Our results suggest a potential link between SLC12A1 gene expression and GLUR4 protein levels with chemoresistance in luminal breast cancer. In particular, GLUR4 protein could serve as a potential target for drug intervention to overcome chemoresistance.

Published
2023

11. A Previously Unrecognized Molecular Landscape of Lynch Syndrome in the Mexican Population

Author

Padua-Bracho, Alejandra, primary, Velázquez-Aragón, José A., additional, Fragoso-Ontiveros, Verónica, additional, Nuñez-Martínez, Paulina María, additional, Mejía Aguayo, María de la Luz, additional, Sánchez-Contreras, Yuliana, additional, Ramirez-Otero, Miguel Angel, additional, De la Fuente-Hernández, Marcela Angélica, additional, Vidal-Millán, Silvia, additional, Wegman-Ostrosky, Talia, additional, Pedroza-Torres, Abraham, additional, Arriaga-Canon, Cristian, additional, Herrera-Montalvo, Luis A., additional, and Alvarez-Gómez, Rosa Maria, additional

Published
2022
Full Text
View/download PDF

12. Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection

Author

Arriaga-Canon, Cristian, primary, Contreras-Espinosa, Laura, additional, Rebollar-Vega, Rosa, additional, Montiel-Manríquez, Rogelio, additional, Cedro-Tanda, Alberto, additional, García-Gordillo, José Antonio, additional, Álvarez-Gómez, Rosa María, additional, Jiménez-Trejo, Francisco, additional, Castro-Hernández, Clementina, additional, and Herrera, Luis A., additional

Published
2022
Full Text
View/download PDF

13. IJMS Supplementary material

Author

Escalante, Jose Alberto Carlos, IlianaMejía-Pérez, Sonia, Soto-Reyes, Ernesto, Guerra-Calderas, Lissania, Cacho-Díaz, Bernardo, Torres-Arciga, Karla, Montalvo-Casimiro, Michel, González-Barrios, Rodrigo, Reynoso-Noverón, Nancy, La Cruz, Miguel Ruiz-De, Díaz-Velázquez, Clara Estela, Vidal-Millán, Silvia, Álvarez-Gómez, Rosa María, Sánchez-Correa, Thalía, Pech-Cervantes, Claudio Hiram, Soria-Lucio, José Antonio, Areli Pérez-Castillo, Salazar-Martínez, Ana María, Arriaga-Canon, Cristian, Vaca-Paniagua, Felipe, González-Arenas, Aliesha, Ostrosky-Wegman, Patricia, Mohar-Betancourt, Alejandro, Herrera, Luis A, Corona, Teresa, and Wegman-Ostrosky, Talia

Subjects
AGT, TP53, MGMT
Abstract

Supplementary material 1: individual patient data from the discovery cohort. Supplementary material 2: supplementary results; table S1: Prevalence of MGMT promoter methylation and MGMT variants patients from the Discovery cohort; table S2: Multivariate Cox regression model for overall survival (OS) in patients from the discovery cohort that received chemotherapy; table S3: Multivariate Cox regression model for OS, including MGMT variants or promoter methylation in patients from the discovery cohort that did not receive chemotherapy; table S4: Multivariate Cox regression model for progression-free survival (PFS), including MGMT variants or promoter methylation and TP53 variants in patients from the discovery cohort that received chemotherapy; table S5: Multivariate Cox regression model for PFS, including MGMT variants or promoter methylation in patients from the discovery cohort that did not receive chemotherapy; table S6: Multivariate Cox regression model for PFS, including AGT variants and MGMT variants or promoter methylation in patients from the discovery cohort; table S7: Validation cohort multivariate Cox regression model. Supplementary material 3: details and annotations of variants detected in the discovery cohort. Supplementary material 4: clinical data of patients from the validation cohort (TCGA). Supplementary material 5: Annotation of AGT, MGMT and TP53 variants from the validation cohort. Supplementary material 6: REMARK checklist for this work. Supplementary material 7: supplementary methods; Primers used in MGMT gene promoter methylation status assessment.

Published
2022
Full Text
View/download PDF

15. Genomic Profile in a Non-Seminoma Testicular Germ-Cell Tumor Cohort Reveals a Potential Biomarker of Sensitivity to Platinum-Based Therapy

Author

González-Barrios, Rodrigo, Alcaraz, Nicolás, Montalvo-Casimiro, Michel, Cervera, Alejandra, Arriaga-Canon, Cristian, Munguia-Garza, Paulina, Hinojosa-Ugarte, Diego, Sobrevilla-Moreno, Nora, Torres-Arciga, Karla, Mendoza-Perez, Julia, Diaz-Chavez, José, Cortes-González, Carlo Cesar, Castro-Hernández, Clementina, Martínez-Cedillo, Jorge, Scavuzzo, Ana, Pérez-Montiel, Delia, Jiménez-Ríos, Miguel A., Herrera, Luis A., González-Barrios, Rodrigo, Alcaraz, Nicolás, Montalvo-Casimiro, Michel, Cervera, Alejandra, Arriaga-Canon, Cristian, Munguia-Garza, Paulina, Hinojosa-Ugarte, Diego, Sobrevilla-Moreno, Nora, Torres-Arciga, Karla, Mendoza-Perez, Julia, Diaz-Chavez, José, Cortes-González, Carlo Cesar, Castro-Hernández, Clementina, Martínez-Cedillo, Jorge, Scavuzzo, Ana, Pérez-Montiel, Delia, Jiménez-Ríos, Miguel A., and Herrera, Luis A.

Abstract

Despite having a favorable response to platinum-based chemotherapies, ~15% of Testicular Germ-Cell Tumor (TGCT) patients are platinum-resistant. Mortality rates among Latin American countries have remained constant over time, which makes the study of this population of particular interest. To gain insight into this phenomenon, we conducted whole-exome sequencing, microarraybased comparative genomic hybridization, and copy number analysis of 32 tumors from a Mexican cohort, of which 18 were platinum-sensitive and 14 were platinum-resistant. We incorporated analyses of mutational burden, driver mutations, and SNV and CNV signatures. DNA breakpoints in genes were also investigated and might represent an interesting research opportunity. We observed that sensitivity to chemotherapy does not seem to be explained by any of the mutations detected. Instead, we uncovered CNVs, particularly amplifications on segment 2q11.1 as a novel variant with chemosensitivity biomarker potential. Our data shed light into understanding platinum resistance in a Latin-origin population.

Published
2022

16. Genomic Profile in a Non-Seminoma Testicular Germ-Cell Tumor Cohort Reveals a Potential Biomarker of Sensitivity to Platinum-Based Therapy

Author

González-Barrios, Rodrigo, primary, Alcaraz, Nicolás, additional, Montalvo-Casimiro, Michel, additional, Cervera, Alejandra, additional, Arriaga-Canon, Cristian, additional, Munguia-Garza, Paulina, additional, Hinojosa-Ugarte, Diego, additional, Sobrevilla-Moreno, Nora, additional, Torres-Arciga, Karla, additional, Mendoza-Perez, Julia, additional, Diaz-Chavez, José, additional, Cortes-González, Carlo Cesar, additional, Castro-Hernández, Clementina, additional, Martínez-Cedillo, Jorge, additional, Scavuzzo, Ana, additional, Pérez-Montiel, Delia, additional, Jiménez-Ríos, Miguel A., additional, and Herrera, Luis A., additional

Published
2022
Full Text
View/download PDF

17. Methylation of Subtelomeric Chromatin Modifies the Expression of the lncRNA TERRA, Disturbing Telomere Homeostasis

Author

Oliva-Rico, Diego, primary, Fabian-Morales, Eunice, additional, Cáceres-Gutiérrez, Rodrigo E., additional, Gudiño, Adriana, additional, Cisneros-Soberanis, Fernanda, additional, Dominguez, Julieta, additional, Almaraz-Rojas, Oscar, additional, Arriaga-Canon, Cristian, additional, Castro-Hernández, Clementina, additional, De la Rosa, Carlos, additional, Reyes, José L., additional, and Herrera, Luis A., additional

Published
2022
Full Text
View/download PDF

19. Proteasome inhibition alters mitotic progression through the upregulation of centromeric α‐Satellite RNAs

Author

Cáceres‐Gutiérrez, Rodrigo E., primary, Andonegui, Marco A., additional, Oliva‐Rico, Diego A., additional, González‐Barrios, Rodrigo, additional, Luna, Fernando, additional, Arriaga‐Canon, Cristian, additional, López‐Saavedra, Alejandro, additional, Prada, Diddier, additional, Castro, Clementina, additional, Parmentier, Laurent, additional, Díaz‐Chávez, José, additional, Alfaro‐Mora, Yair, additional, Navarro‐Delgado, Erick I., additional, Fabian‐Morales, Eunice, additional, Tran, Bao, additional, Shetty, Jyoti, additional, Zhao, Yongmei, additional, Alcaraz, Nicolas, additional, De la Rosa, Carlos, additional, Reyes, José L., additional, Hédouin, Sabrine, additional, Hubé, Florent, additional, Francastel, Claire, additional, and Herrera, Luis A., additional

Published
2021
Full Text
View/download PDF

22. Proteasome inhibition alters mitotic progression through the upregulation of centromeric α‐Satellite RNAs.

Author

Cáceres‐Gutiérrez, Rodrigo E., Andonegui, Marco A., Oliva‐Rico, Diego A., González‐Barrios, Rodrigo, Luna, Fernando, Arriaga‐Canon, Cristian, López‐Saavedra, Alejandro, Prada, Diddier, Castro, Clementina, Parmentier, Laurent, Díaz‐Chávez, José, Alfaro‐Mora, Yair, Navarro‐Delgado, Erick I., Fabian‐Morales, Eunice, Tran, Bao, Shetty, Jyoti, Zhao, Yongmei, Alcaraz, Nicolas, De la Rosa, Carlos, and Reyes, José L.

Subjects
PROTEOLYSIS, MITOSIS regulation, RNA, RNA regulation, CELL cycle, COHESINS, PROTEASOMES
Abstract

Cell cycle progression requires control of the abundance of several proteins and RNAs over space and time to properly transit from one phase to the next and to ensure faithful genomic inheritance in daughter cells. The proteasome, the main protein degradation system of the cell, facilitates the establishment of a proteome specific to each phase of the cell cycle. Its activity also strongly influences transcription. Here, we detected the upregulation of repetitive RNAs upon proteasome inhibition in human cancer cells using RNA‐seq. The effect of proteasome inhibition on centromeres was remarkable, especially on α‐Satellite RNAs. We showed that α‐Satellite RNAs fluctuate along the cell cycle and interact with members of the cohesin ring, suggesting that these transcripts may take part in the regulation of mitotic progression. Next, we forced exogenous overexpression and used gapmer oligonucleotide targeting to demonstrate that α‐Sat RNAs have regulatory roles in mitosis. Finally, we explored the transcriptional regulation of α‐Satellite DNA. Through in silico analyses, we detected the presence of CCAAT transcription factor‐binding motifs within α‐Satellite centromeric arrays. Using high‐resolution three‐dimensional immuno‐FISH and ChIP‐qPCR, we showed an association between the α‐Satellite upregulation and the recruitment of the transcription factor NFY‐A to the centromere upon MG132‐induced proteasome inhibition. Together, our results show that the proteasome controls α‐Satellite RNAs associated with the regulation of mitosis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. Radio-miRs: a comprehensive view of radioresistance-related microRNAs

Author

Pedroza-Torres, Abraham, Romero-Córdoba, Sandra L, Montaño, Sarita, Peralta-Zaragoza, Oscar, Vélez-Uriza, Dora Emma, Arriaga-Canon, Cristian, Guajardo-Barreto, Xiadani, Bautista-Sánchez, Diana, Sosa-León, Rodrigo, Hernández-González, Olivia, Díaz-Chávez, José, Alvarez-Gómez, Rosa María, and Herrera, Luis A

Abstract

Radiotherapy is a key treatment option for a wide variety of human tumors, employed either alone or alongside with other therapeutic interventions. Radiotherapy uses high-energy particles to destroy tumor cells, blocking their ability to divide and proliferate. The effectiveness of radiotherapy is due to genetic and epigenetic factors that determine how tumor cells respond to ionizing radiation. These factors contribute to the establishment of resistance to radiotherapy, which increases the risk of poor clinical prognosis of patients. Although the mechanisms by which tumor cells induce radioresistance are unclear, evidence points out several contributing factors including the overexpression of DNA repair systems, increased levels of reactive oxygen species, alterations in the tumor microenvironment, and enrichment of cancer stem cell populations. In this context, dysregulation of microRNAs or miRNAs, critical regulators of gene expression, may influence how tumors respond to radiation. There is increasing evidence that miRNAs may act as sensitizers or enhancers of radioresistance, regulating key processes such as the DNA damage response and the cell death signaling pathway. Furthermore, expression and activity of miRNAs have shown informative value in overcoming radiotherapy and long-term radiotoxicity, revealing their potential as biomarkers. In this review, we will discuss the molecular mechanisms associated with the response to radiotherapy and highlight the central role of miRNAs in regulating the molecular mechanisms responsible for cellular radioresistance. We will also review radio-miRs, radiotherapy-related miRNAs, either as sensitizers or enhancers of radioresistance that hold promise as biomarkers or pharmacological targets to sensitize radioresistant cells.

Published
2024
Full Text
View/download PDF

24. MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities

Author

Pedroza-Torres, Abraham, primary, Romero-Córdoba, Sandra L., additional, Justo-Garrido, Montserrat, additional, Salido-Guadarrama, Iván, additional, Rodríguez-Bautista, Rubén, additional, Montaño, Sarita, additional, Muñiz-Mendoza, Rodolfo, additional, Arriaga-Canon, Cristian, additional, Fragoso-Ontiveros, Verónica, additional, Álvarez-Gómez, Rosa María, additional, Hernández, Greco, additional, and Herrera, Luis A., additional

Published
2019
Full Text
View/download PDF

25. Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients

Author

Fragoso-Ontiveros, Veronica, primary, Velázquez-Aragón, Jose Antonio, additional, Nuñez-Martínez, Paulina Maria, additional, de la Luz Mejía-Aguayo, Maria, additional, Vidal-Millán, Silvia, additional, Pedroza-Torres, Abraham, additional, Sánchez-Contreras, Yuliana, additional, Ramírez-Otero, Miguel Angel, additional, Muñiz-Mendoza, Rodolfo, additional, Domínguez-Ortíz, Julieta, additional, Wegman-Ostrosky, Talia, additional, Bargalló-Rocha, Juan Enrique, additional, Gallardo-Rincón, Dolores, additional, Reynoso-Noveron, Nancy, additional, Arriaga-Canon, Cristian, additional, Meneses-García, Abelardo, additional, Herrera-Montalvo, Luis Alonso, additional, and Alvarez-Gomez, Rosa Maria, additional

Published
2019
Full Text
View/download PDF

28. Molecular features of influenza A (H1N1)pdm09 prevalent in Mexico during winter seasons 2012-2014

Author

Arellano-Llamas, Rocío, primary, Alfaro-Ruiz, Luis, additional, Arriaga Canon, Cristian, additional, Imaz Rosshandler, Ivan, additional, Cruz-Lagunas, Alfredo, additional, Zúñiga, Joaquín, additional, Rebollar Vega, Rosa, additional, Wong, Christopher W., additional, Maurer-Stroh, Sebastian, additional, Romero Córdoba, Sandra, additional, Liu, Edison T., additional, Hidalgo-Miranda, Alfredo, additional, and Vázquez-Pérez, Joel A., additional

Published
2017
Full Text
View/download PDF

33. Transcriptome Analysis Identifies GATA3-AS1as a Long Noncoding RNA Associated with Resistance to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

Author

Contreras-Espinosa, Laura, Alcaraz, Nicolás, De La Rosa-Velázquez, Inti A., Díaz-Chávez, José, Cabrera-Galeana, Paula, Vega, Rosa R., Reynoso-Noveron, Nancy, Maldonado-Martínez, Héctor A., González-Barrios, Rodrigo, Montiel-Manríquez, Rogelio, Bautista-Sánchez, Diana, Castro-Hernández, Clementina, Álvarez-Gómez, Rosa M., Jiménez-Trejo, Francisco, Tapia-Rodríguez, Miguel, García-Gordillo, José, Pérez-Rosas, Augusto, Bargallo-Rocha, Enrique, Arriaga-Canon, Cristian, and Herrera, Luis A.

Abstract

Breast cancer is one of the leading causes of mortality in women worldwide, and neoadjuvant chemotherapy has emerged as an option for the management of locally advanced breast cancer. Extensive efforts have been made to identify new molecular markers to predict the response to neoadjuvant chemotherapy. Transcripts that do not encode proteins, termed long noncoding RNAs (lncRNAs), have been shown to display abnormal expression profiles in different types of cancer, but their role as biomarkers in response to neoadjuvant chemotherapy has not been extensively studied. Herein, lncRNA expression was profiled using RNA sequencing in biopsies from patients who subsequently showed either response or no response to treatment. The GATA3-AS1transcript was overexpressed in the nonresponder group and was the most stable feature when performing selection in multiple random forest models. GATA3-AS1was experimentally validated by RT-qPCR in an extended group of 68 patients. Expression analysis confirmed that GATA3-AS1is overexpressed primarily in patients who were nonresponsive to neoadjuvant chemotherapy, with a sensitivity of 92.9%, a specificity of 75.0%, and an area under the curve of approximately 0.90, as measured by receiver operating characteristic curve analysis. The statistical model was based on luminal B-like patients and adjusted by menopausal status and phenotype (odds ratio, 37.49; 95% CI, 6.74–208.42; P = 0.001); GATA3-AS1was established as an independent predictor of response. Thus, lncRNA GATA3-AS1is proposed as a potential predictive biomarker of nonresponse to neoadjuvant chemotherapy.

Published
2021
Full Text
View/download PDF

34. A Molecular Characterization of the Allelic Expression of the BRCA1 Founder Δ9-12 Pathogenic Variant and Its Potential Clinical Relevance in Hereditary Cancer.

Author

Dominguez-Ortiz J, Álvarez-Gómez RM, Montiel-Manríquez R, Cedro-Tanda A, Alcaraz N, Castro-Hernández C, Bautista-Hinojosa L, Contreras-Espinosa L, Torres-Maldonado L, Fragoso-Ontiveros V, Sánchez-Contreras Y, González-Barrios R, Fuente-Hernández MA, Mejía-Aguayo ML, Juárez-Figueroa U, Padua-Bracho A, Sosa-León R, Obregon-Serrano G, Vidal-Millán S, Núñez-Martínez PM, Pedroza-Torres A, Nicasio-Arzeta S, Rodríguez A, Luna F, Cisneros-Soberanis F, Frías S, Arriaga-Canon C, and Herrera-Montalvo LA

Subjects
Humans, Female, Middle Aged, Genetic Predisposition to Disease, Adult, Founder Effect, Exons genetics, Breast Neoplasms genetics, Heterozygote, Mutation, Mexico, Ovarian Neoplasms genetics, Clinical Relevance, BRCA1 Protein genetics, Alleles, Hereditary Breast and Ovarian Cancer Syndrome genetics
Abstract

Hereditary breast and ovarian cancer (HBOC) syndrome is a genetic condition that increases the risk of breast cancer by 80% and that of ovarian cancer by 40%. The most common pathogenic variants (PVs) causing HBOC occur in the BRCA1 gene, with more than 3850 reported mutations in the gene sequence. The prevalence of specific PVs in BRCA1 has increased across populations due to the effect of founder mutations. Therefore, when a founder mutation is identified, it becomes key to improving cancer risk characterization and effective screening protocols. The only founder mutation described in the Mexican population is the deletion of exons 9 to 12 of BRCA1 ( BRCA1 Δ9-12 ), and its description focuses on the gene sequence, but no transcription profiles have been generated for individuals who carry this gene. In this study, we describe the transcription profiles of cancer patients and healthy individuals who were heterozygous for PV BRCA1 Δ9-12 by analyzing the differential expression of both alleles compared with the homozygous BRCA1 control group using RT-qPCR, and we describe the isoforms produced by the BRCA1 wild-type and BRCA1 Δ9-12 alleles using nanopore long-sequencing. Using the Kruskal-Wallis test, our results showed a similar transcript expression of the wild-type allele between the healthy heterozygous group and the homozygous BRCA1 control group. An association between the recurrence and increased expression of both alleles in HBOC patients was also observed. An analysis of the sequences indicated four wild-type isoforms with diagnostic potential for discerning individuals who carry the PV BRCA1 Δ9-12 and identifying which of them has developed cancer.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results